Actelion and J&J Circle Back to Negotiating Table

The transcript discusses the unexpected developments in a major deal involving J&J and Actelion. Initially thought to be off, the deal faced complications due to contingent value rights and experimental drug performance. Investors prefer a straightforward takeover by J&J, but the companies remain tight-lipped. Market speculation is high, with pricing discrepancies noted between J&J and Santa Fe's offers, leading to uncertainty about the final outcome.

What complications arose during the discussions about the deal mentioned in the text?

What do investors prefer regarding the deal structure, according to the text?

What was the price range discussed for the deal involving J&J?

What was the initial price thought to be from J&J before the discussions?

How did the speaker feel about the likelihood of closing the price gap mentioned?